Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (ALTITUDE)
To determine whether, in patients with type II diabetes and pre-existing disease of the heart and the circulatory system and/or kidney, aliskiren at a target dose of 300 mg once daily (compared to placebo), on top of conventional treatment, reduces death and disease caused by the heart, the circulatory system and the kidney. Sponsored by Novartis.
Enrolling. Yes. Participants must be 35 or older, with type II diabetes and at least one of the following: - macroalbuminuria - microalbuminuria and a reduced kidney function - previous heart attack and a reduced kidney function - previous stroke and a reduced kidney function - heart failure and a reduced kidney function, or - coronary artery disease and a reduced kidney function. Concomitant treatment should follow national guidelines and must include either an Angiotensin-converting-enzyme-inhibitor (ACEi) or an Angiotensin-receptor-blocker (ARB), but not both.
July 01, 2007
Zachary R. Freedman, MD, FACE
Amy Winterberger, CCRC